Medtep Competitors and Similar CompaniesClear all
Durect's competitors and similar companies include Affimed N.V. and BTG.
 Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases. |  Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. | ||
Founding Date | Founding Date N/A | Founding Date 2000 | Founding Date 1948 |
Type | Type Public | Type Public | Type Subsidiary |
Tags | |||
Locations | Locations Cupertino, US HQ | Locations Heidelberg, DE HQ | |
Employees | Employees 902% increase | Employees 76 | Employees 650 |
Valuation ($) | Valuation ($) 45.3 m | Valuation ($) 52.5 m | Valuation ($) N/A |
Financial | |||
Revenue (est.) | Revenue (est.) $2m (FY, 2024) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) £731.3m (FY, 2019) |
Cost of goods | Cost of goods $78k (FY, 2024) | Cost of goods N/A | Cost of goods £221m (FY, 2019) |
Gross profit | Gross profit $2m (FY, 2024) | Gross profit €13m (FY, 2023) | Gross profit £510.3m (FY, 2019) |
Net income | Net income ($8.3m) (FY, 2024) | Net income (€105.9m) (FY, 2023) | Net income £88.3m (FY, 2019) |
For sources of this data, please see the company profile
View Company Profiles
Affimed N.V.
HQ
Heidelberg, DE
Employees
76
Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
View company